Format

Send to

Choose Destination
J Thorac Oncol. 2019 Nov;14(11):1881-1883. doi: 10.1016/j.jtho.2019.08.005.

Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments.

Author information

1
Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain. Electronic address: esnadal@iconcologia.net.
2
Department of Medical Oncology, Catalan Institute of Oncology, Clinical Research in Solid Tumors (CReST) Group, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain.
3
Cell Death Regulation Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain.
PMID:
31668314
DOI:
10.1016/j.jtho.2019.08.005

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center